Congo approves clinical trials for Ebola treatments


KINSHASA (Reuters) – Congolese authorities have authorized clinical trials for four experimental Ebola treatments, the health ministry said on Saturday.

FILE PHOTO: A doctor for an isolated patient at the International Alliance (ALIMA) treatment center in Beni, North Kivu province of the Democratic Republic of Congo September 6, 2018. REUTERS / Fiston Mahamba / File Photo

Ebola patients since August in an attempt to contain the worst of the Democratic Republic of Congo's outbreaks of the hemorrhagic fever since 1976.

But until now doctors have decided which case-by-case basis. In the clinical trial, the choice of treatment will now be randomized.

The ministry added in a statement.

The ministry said. "Precious information about the effectiveness of the treatment in the clinical trial.

The four treatments are mAb114, which was developed by the U.S. government; ZMapp, an intravenous treatment made by Mapp Biopharmaceutical; Remdesivir, made by Gilead Sciences; and Regeneron's REGN-EB3.

As of last weekend, 151 patients had received one of the four drugs. Of those, 76 had recovered, 44 had died and 31 were still hospitalized – a mortality rate of 37 percent.

Mortality rate was close to 80 percent by contrast.

The ministry said that the outcome of the current outbreak would probably not be sufficient to make definitive conclusions about the efficacy of the treatments.

Despite the use of the vaccine manufactured by Merck, authorities have struggled to contain the two outcomes of resistance to health workers.

At least 228 people are believed to have died, and the World Health Organization said last week that expects the outbreak to last at least another six months.

Reporting By Giulia Paravicini; Editing by Aaron Ross

Our Standards:The Thomson Reuters Trust Principles.



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.